Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Inhibidores de exportación nuclear con actividad antitumoral y antiviral

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TODE20151020001
Publicado:
02/11/2015
Caducidad:
01/11/2016
Resumen:
Una universidad alemana ofrece compuestos de bajo peso molecular para inhibir la exportación nuclear de factores celulares virales y estimuladores de tumores. Estos compuestos están indicados para el tratamiento y profilaxis de enfermedades neoplásicas o virales. Se buscan socios industriales e investigadores para identificar y evaluar la eficacia antiviral y antitumoral de los compuestos dentro de modelos in vitro e in vivo. La universidad esta interesada en establecer acuerdos de licencia exclusivos y no exclusivos con el fin de explotar los resultados del proyecto.

Details

Tittle:
Nuclear export inhibitors with anti-tumoral and anti-viral activity
Summary:
A German university provides low molecular weight compounds inhibiting the nuclear export of viral and tumor-promoting cellular factors. They are therefore suited for the treatment and prophylaxis of neoplastic or viral diseases. Researchers are looking for industrial and research partners to further identify and evaluate the anti-viral and anti-tumoral efficacy of compounds within in-vitro and in-vivo models. Exclusive or non-exclusive licensing is possible.
Description:
A German university has found certain low molecular weight compounds with a nuclear export of viral and tumor-promoting cellular factors.

Regulated nucleo-cytoplasmic transport of pathobiologically relevant proteins is critical for tumor development and viral diseases. Transport is mediated by nuclear export signals (NESs) interacting with the export receptor CRM1. NESs have been identified in numerous disease relevant cellular and viral proteins. Hence, the pharmacogenetic interference with nuclear export provides an attractive and novel therapeutic principle to rationally control and target the activity of such disease factors.
The inventors identified three nuclear export inhibitors (NEIs) by high-throughput cell based translocation screens with shown anti-tumoral and anti-viral activities. As such, these drugs may represent a hitherto neglected additional pillar for combination treatment of human diseases.

For the first time these NEIs allow to achieving a reversible or irreversible (depending on the compound) mode of export inhibition in solid and liquid cancer cell lines. Treatment resulted in inhibition of cell proliferation, induction of apoptosis and also affected HIV-1 replication in cell models. Moreover, combining the novel NEIs with chemotherapeutic drugs currently used in the clinics resulted in an additional increase in tumor cell killing.

In contrast to what is observed in cancer cells, these agents do not affect the viability of normal fibroblasts, and are not toxic in nude mice. Therefore this invention provides novel NEIs with potential clinical efficacy for the treatment and/or prophylaxis of cancer or viral diseases.

Further tasks to be performed:

The targeted modulation of nucleo-zytoplasmatic transport processes shall be followed as a therapeutic strategy against both viral and cancer diseases.

In this context the research group is open for various kinds of cooperation with academic and industrial partners. Cooperation is possible on the basis of private investment with industrial partners or within a European public funded research cooperation with academic and / or industrial partners.

The group has developed specific cell-based test systems, which allow to identify and evaluate the anti-viral and anti-tumoral efficacy of compounds within in-vitro and in-vivo models.

Partners are needed in order to carry out the following studies:

a) Profiling and functional characterization of export inhibitors in cancer cell-lines or in virology

b) In vitro and in vivo toxicity profiling of NEIs

c) Testing of anti-tumoral activities of the inhibitors in murine tumor-transplantation modells

d) Investigation and classification of chemical inhibitor derivates

e) Identification and characterisation of target molecules of NEIs

Exclusive and non-exclusive licensing of compounds is possible for industrial partners in order to assure economic exploitation of of project results.
Advantages and Innovations:
· Successful treatment or prophylaxis of cancer or viral diseases

· Reversible or irreversible mode of export inhibition in cancer cell lines

· Nuclear Export Inhibitors (NEI) synergize with currently used chemotherapeutics in cancer cell killing

· Nontoxic in normal cell lines
Stage of Development:
Under development/lab tested
IPs:
Patents granted
CommeR Statunts Regarding IPR Status:
Patents granted in Germany, UK, France

Partner sought

Type and Role of Partner Sought:
Type of partner sought:

Pharmaceutical industry and research organisations developing drugs against viral diseases or cancer

The ideal partner should:

· be active in virology or oncology
· be interested in nuclear export inhibitors
· have a commercial interest in developing and marketing medicaments against viral diseases or cancer or / and
· be likely to in-licensing of the invention


Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German

Keywords

Technology Keywords:
06002002 Biología celular y molecular
06001003 Citología, cancerología, oncología
06002007 Ensayos in vitro, experimentos
06001015 Productos farmacéuticos / medicamentos
06001018 Virus, virología / antibióticos / bacteriología